Literature DB >> 28699269

Determinants of short and long term outcomes in patients undergoing immediate breast reconstruction following neoadjuvant chemotherapy.

Craig A Wengler1, Stephanie A Valente1, Zahraa Al-Hilli1, Neil M Woody2, Julia H Muntean1, Jame Abraham3, Rahul D Tendulkar2, Risal Djohan4, Colin O'Rourke5, Joseph P Crowe1, Stephen R Grobmyer1.   

Abstract

BACKGROUND: We evaluated oncologic outcomes and complications of skin-sparing mastectomy (SSM) and nipple-sparing mastectomy (NSM) with immediate reconstruction (IR) after neoadjuvant chemotherapy (NAC) in patients with early-stage and locally advanced breast cancer (BC).
METHODS: BC patients from 2000 to 2014 treated with NAC followed by SSM/NSM and IR were reviewed. Patient demographics, tumor characteristics, NAC response, complications, and recurrence were analyzed.
RESULTS: Two hundred sixty-nine patients with 280 BCs were treated with NAC followed by SSM (94%) or NSM (6%) with IR. Median age was 47 (26-72) years with a median follow-up of 45 months. Pathologic complete response (pCR) was noted in 49 (17.5%) cases. Overall 30-day complication rate was 13.2%. Variables associated with complications included BMI (P < 0.0001), tobacco use (P = 0.015), and adjuvant radiation (P = 0.025). Local-regional recurrence was 3.2% and metastatic recurrence was 13.2%. Variables predicting recurrence risk were pre-NAC tumor size (P < 0.001), residual tumor size (P = 0.002), Grade III (P = 0.002), HER-2 negative (P = 0.025), pre-NAC nodal disease (P = 0.05), and lack of pCR (P = 0.045).
CONCLUSION: Following NAC, risk factors for complications in patients undergoing SSM/NSM with IR are high BMI, smoking, and adjuvant XRT. SSM/NSM following NAC is associated with excellent local control. These data support expanding the indications for NSM/SSM to include patients receiving NAC.
© 2017 Wiley Periodicals, Inc.

Entities:  

Keywords:  breast cancer; immediate reconstruction; neoadjuvant chemotherapy; nipple-sparing mastectomy; skin-sparing mastectomy

Mesh:

Year:  2017        PMID: 28699269     DOI: 10.1002/jso.24741

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  6 in total

1.  A propensity score-matched comparison of recurrence outcomes after immediate implant vs autologous flap reconstruction in patients receiving neoadjuvant chemotherapy for breast cancer.

Authors:  Zhen-Yu Wu; Hyun Ho Han; Hee Jeong Kim; Jong Won Lee; Il Yong Chung; Jisun Kim; Sae Byul Lee; Byung-Ho Son; Jin Sup Eom; Jae Ho Jung; Sung- Bae Kim; Gyungyub Gong; Hak Hee Kim; Sei -Hyun Ahn; BeomSeok Ko
Journal:  Breast Cancer Res Treat       Date:  2021-03-19       Impact factor: 4.872

Review 2.  Overview of indications for nipple sparing mastectomy.

Authors:  Eleni Tousimis; Michelle Haslinger
Journal:  Gland Surg       Date:  2018-06

3.  Effectiveness and Safety of Implant-Based Breast Reconstruction in Locally Advanced Breast Carcinoma: A Matched Case-Control Study.

Authors:  René Aloisio da Costa Vieira; Luciana Machado Ribeiro; Guilherme Freire Angotti Carrara; Lucas Faria Abrahão-Machado; Ligia Maria Kerr; Afonso Celso Pinto Nazário
Journal:  Breast Care (Basel)       Date:  2019-05-03       Impact factor: 2.860

4.  Reconstructive outcome analysis of the impact of neoadjuvant chemotherapy on immediate breast reconstruction: a retrospective cross-sectional study.

Authors:  Jia-Ruei Yang; Wen-Ling Kuo; Chi-Chang Yu; Shin-Cheh Chen; Jung-Ju Huang
Journal:  BMC Cancer       Date:  2021-05-08       Impact factor: 4.430

5.  Latissimus dorsi myocutaneous flap repair is effective after neoadjuvant chemotherapy for locally advanced breast cancer.

Authors:  Lu Li; Yue Yang; Wang Li; Xian Zhao; Jia He; Shuo Mei; Xuejun Guo; Xibin Zhang; Jianghua Ran
Journal:  World J Surg Oncol       Date:  2022-04-27       Impact factor: 3.253

6.  Factors Predicting Locoregional Recurrence After Neoadjuvant Chemotherapy and Nipple-Sparing/Skin-Sparing Mastectomy With Immediate Breast Reconstruction.

Authors:  Zhen-Yu Wu; Hee Jeong Kim; Jong Won Lee; Il Yong Chung; Jisun Kim; Sae Byul Lee; Byung-Ho Son; Jin Sup Eom; Jae Ho Jeong; Gyungyub Gong; Hak Hee Kim; Sei-Hyun Ahn; BeomSeok Ko
Journal:  Front Oncol       Date:  2021-07-01       Impact factor: 6.244

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.